

CellMax colon cancer screening study

February 2019—CellMax Life announced the kickoff of its Zenith study, a U.S. clinical study for the company's circulating tumor cell blood test. CellMax is partnering with the U.S. Department of Veterans Affairs, Stanford Medicine, and Johns Hopkins to conduct the study, in which patients 45 years and older will receive the CellMax blood test, and the performance of the test will be compared with colonoscopy as the gold standard.

[CellMax Life](#), 650-564-3905